Bioaccelerate Holdings

Bioaccelerate Holdings was a life sciences investment and holding company founded by prominent biotech entrepreneur Sir Chris Evans. The company specialized in identifying and developing high-potential biotechnology, pharmaceutical, and medical device technologies through its portfolio of subsidiary companies. Bioaccelerate provided strategic management and capital to accelerate the commercialization of early-stage life science innovations. The company was publicly traded on the OTC market under the symbol BACL before ceasing active operations. Its portfolio included diverse interests in drug discovery, diagnostics, and medical devices, with notable holdings in companies such as Celsis and ExonHit Therapeutics. The firm aimed to bridge the gap between laboratory innovation and commercial success by providing a structured path for development and exit.